Trenbolone 200

Dragon Pharma Trenbolone 200 – Trenbolone Enanthate 200 mg/mL

Trenbolone 200 by Dragon Pharma is an injectable product containing 200 mg/mL of Trenbolone Enanthate. Trenbolone is a highly potent anabolic-androgenic steroid, while the enanthate ester provides a longer-release formulation compared with shorter-acting trenbolone esters.

Each vial contains 10 mL of solution at the stated concentration of 200 mg/mL. Trenbolone does not aromatize directly into estrogen, but it has progestogenic activity and can produce significant hormonal, cardiovascular, neurological, androgenic, and metabolic effects.

Customers comparing longer-acting injectable formulations can browse the broader injectable products category, including products such as Enantat 250, Cypionat 250, and Masteron. These products contain different active substances and should not be considered direct substitutes.

About the Active Substance

Trenbolone is a synthetic anabolic-androgenic steroid structurally related to nandrolone. It binds strongly to the androgen receptor and is associated with pronounced effects on muscle protein metabolism, nitrogen retention, body composition, and strength.

The enanthate ester slows the release of trenbolone after administration. This changes the release profile compared with shorter esters but does not reduce the underlying systemic risks associated with trenbolone exposure.

Unlike testosterone, trenbolone itself does not aromatize into estrogen. However, its progestogenic properties and strong suppression of endogenous hormone production mean that endocrine effects can still be substantial.

Key Product Characteristics

• 200 mg/mL of Trenbolone Enanthate
• 10 mL manufacturer vial
• Long-acting injectable formulation
• Does not aromatize directly into estrogen
• Progestogenic activity
• Multiple analytical potency reports available
• Latest listed result: 201.97 mg/mL

Product Details

Use, Health Risks & Medical Considerations

How Trenbolone Enanthate Is Commonly Described

Trenbolone Enanthate is a long-acting injectable formulation of trenbolone. In performance-oriented settings, trenbolone is associated with substantial anabolic and androgenic activity and is frequently discussed in relation to changes in strength, lean tissue, and body composition.

Such effects should not be separated from the compound's risk profile. Trenbolone can produce pronounced endocrine suppression and may adversely affect cardiovascular markers, sleep, mood, exercise tolerance, and sexual function.

Trenbolone is sometimes discussed alongside testosterone formulations such as Enantat 250 or Cypionat 250. Combining anabolic substances increases complexity and can intensify cardiovascular, hormonal, neurological, and other adverse effects.

Important Risk Areas

• Cardiovascular system: Trenbolone and other anabolic steroids may adversely affect blood pressure, HDL and LDL cholesterol, vascular function, cardiac structure, and overall cardiovascular risk.
• Hormonal system: Trenbolone can cause substantial suppression of endogenous testosterone production and may affect fertility, libido, mood, and sexual function.
• Progestogenic effects: Trenbolone has progestogenic activity, which may contribute to complex endocrine effects even though the compound does not directly aromatize into estrogen.
• Androgenic effects: Acne, oily skin, increased body-hair growth, and accelerated scalp-hair loss in genetically predisposed individuals may occur.
• Sleep and neurological effects: Insomnia, night sweats, anxiety, irritability, mood changes, and disturbed sleep are frequently discussed in association with trenbolone exposure.
• Exercise tolerance: Some users report reduced cardiovascular endurance or shortness of breath during exertion.
• Injection-related risks: Injectable products carry risks including pain, irritation, infection, abscess formation, tissue injury, and complications associated with non-sterile administration.

Monitoring Considerations

A licensed clinician may consider reviewing blood pressure, complete blood count, fasting lipids, liver and kidney markers, glucose markers, and reproductive hormone levels based on the individual's circumstances.

Testing does not make non-medical anabolic-steroid use safe, but medical assessment may identify emerging abnormalities that would otherwise remain unnoticed.

Drug and Health Interactions

Risk may be greater in people with cardiovascular disease, high blood pressure, abnormal cholesterol, kidney or liver disease, clotting disorders, prostate conditions, diabetes, psychiatric conditions, or a history of hormone-sensitive disease.

Potential interactions may occur with anticoagulants, diabetes medications, corticosteroids, hormone therapies, blood-pressure medications, and other performance-enhancing substances. A qualified clinician or pharmacist should review possible interactions.

Hormonal Recovery Considerations

Trenbolone can strongly suppress endogenous hormone production. Products such as Nolvadex, Clomid, and HCG are sometimes discussed in relation to hormonal management or post-use recovery, but they are separate medications with their own indications, contraindications, and adverse effects.

No universal post-cycle or hormone-management protocol is appropriate for every person. Self-prescribing additional medications can mask symptoms, worsen hormone imbalance, or create further drug interactions.

Who Should Not Use It

• Children and adolescents
• People who are pregnant, trying to become pregnant, or breastfeeding
• People with uncontrolled high blood pressure or significant cardiovascular disease
• Anyone with serious liver or kidney disease
• Anyone with prostate, breast, or another hormone-sensitive cancer
• People with significant psychiatric or mood disorders without medical assessment
• Competitive athletes subject to anti-doping rules
• Anyone using the product without understanding applicable local laws

When to Seek Urgent Medical Care

Seek urgent medical attention for chest pain, severe shortness of breath, fainting, one-sided weakness, severe headache, jaundice, rapidly worsening swelling, severe psychological disturbance, signs of a serious allergic reaction, or an injection site that becomes increasingly painful, hot, swollen, or accompanied by fever.

Analytical Potency Reports

The reports below display the measured concentration reported for submitted samples of Dragon Pharma Trenbolone 200. The newest listed report appears first, followed by earlier reports for historical comparison.

A potency result evaluates the measured amount of the reported active substance in the submitted sample. It does not independently establish clinical safety, manufacturing compliance, legal status, sterility, freedom from every possible contaminant, or suitability for use.

Lab file

trenbolone-200-lab-test-2026-08-24

Test Date

2026-08-24

Label Strength

200 mg/mL

Measured Result

201.97 mg/mL

Assay vs Label

100.99%

Batch

TREHD6

Report summary: The submitted Trenbolone 200 sample from batch TREHD6 measured 201.97 mg/mL against the stated 200 mg/mL label strength.

Latest Report

Previous Reports

Lab file

tren-200-lab-test-2025-04-18

Test Date

2025-04-18

Label Strength

200 mg/mL

Measured Result

211.78 mg/mL

Assay vs Label

105.89%

Report summary: The submitted sample measured 211.78 mg/mL, equivalent to 105.89% of the stated 200 mg/mL label strength.

Previous Report

Lab file

tren-200-lab-test-2025-01-17

Test Date

2025-01-17

Label Strength

200 mg/mL

Measured Result

197.48 mg/mL

Assay vs Label

98.74%

Report summary: The submitted sample measured 197.48 mg/mL, equivalent to 98.74% of the stated 200 mg/mL label strength.

Previous Report

Lab file

tren-200-lab-test-2024-05-16

Test Date

2024-05-16

Label Strength

200 mg/mL

Measured Result

218.64 mg/mL

Assay vs Label

109.32%

Report summary: The submitted sample measured 218.64 mg/mL, equivalent to 109.32% of the stated 200 mg/mL label strength.

Previous Report

Authenticity, Delivery Information & Legal Notice

Product-Identification Checks

• Compare the product name and stated strength with the order and packaging
• Confirm that the vial identifies Dragon Pharma and Trenbolone Enanthate
• Check that the label states 200 mg/mL and a 10 mL presentation
• Inspect the vial, cap, seal, print quality, and overall packaging condition
• Look for available batch or date information where present
• Compare analytical documents only with the corresponding product and submitted sample
• Do not use products that appear opened, relabeled, leaking, contaminated, or damaged

Delivery and Tracking Information

Delivery times, tracking availability, customs handling, and reshipment eligibility depend on the selected warehouse, destination, carrier, and current store policy. Review the complete Shipping Information page before placing an order.

Tracking events may not appear immediately, and some carriers scan parcels only after they reach a regional or destination facility. A temporary lack of tracking activity does not by itself confirm that a shipment has been lost.

Sports Eligibility

Trenbolone is prohibited in competitive sport under anti-doping rules. Athletes are responsible for every prohibited substance detected in their samples, regardless of how the substance was obtained or labeled.

Additional Store Information

For broader information about product verification, store policies, and supporting sources, review the site's References, Terms and Conditions, and Privacy Policy.

Medical Disclaimer

Nothing on this page should be interpreted as diagnosis, treatment, prescribing guidance, or an assurance that this product is appropriate for a particular person. Consult a qualified clinician and verify the laws that apply in your jurisdiction.

Storage & Handling

Keep Trenbolone 200 in its original labeled vial and packaging unless the manufacturer labeling specifies otherwise. Protect the product from excessive heat, direct sunlight, and inappropriate storage conditions.

• Keep the vial in its original labeled packaging
• Protect from excessive heat and direct sunlight
• Do not use a vial with a damaged or compromised closure
• Do not combine the contents of different vials or batches
• Keep away from children, pets, and unauthorized users
• Do not use solution that appears unexpectedly discolored, contaminated, or contains unexplained visible material

Do not use the product if the vial has been opened unexpectedly, the closure appears compromised, the label is unreadable, or the contents differ materially from their expected appearance.

For disposal guidance, contact a pharmacist or an authorized medication take-back service. Do not share controlled substances with another person.

Storage instructions printed on the original product packaging should take priority when they are more specific.

Frequently Asked Questions